The Ministry of Health and Child Care has confirmed the recall of two batches of the blood pressure medication Nifedipine 10mg after quality testing revealed the tablets no longer meet required standards. The recall, ordered by the Medicines Control Authority of Zimbabwe (MCAZ), affects batches 112033 and 117367 manufactured by Remedica Ltd, a pharmaceutical company based in Cyprus.
In a statement issued on 12 September 2026, the Ministry said the recall forms part of the Authority’s routine post-market surveillance activities. The affected tablets are used for the management of high blood pressure and certain heart-related conditions, making the recall a significant public health matter.
The MCAZ has classified this as a Class Two recall, which extends down to retail level. This means the affected stock must be withdrawn from pharmacies and health facilities, and patients who may already have the medication in their possession are advised to check the batch numbers on their packaging.
The same round of testing also flagged quality issues with Levodopa/Carbidopa tablets, also manufactured by Remedica Ltd, which are used in the treatment of Parkinson’s disease and Parkinsonism. The MCAZ has not yet specified the exact batches affected for this second drug.
Patients taking Nifedipine 10mg are urged to verify the batch number on their medication. If the batch matches 112033 or 117367, they should stop taking the tablets and consult their healthcare provider for alternative treatment. Do not discontinue blood pressure medication without medical advice, as sudden cessation can be dangerous.
This recall underscores the importance of MCAZ’s regulatory oversight in protecting public health. Zimbabweans are encouraged to report any adverse effects or suspicious medication to the nearest health facility or the MCAZ.
